查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1880593

重组白蛋白市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032）

Recombinant Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

重组白蛋白市场成长因子

由于生物製药、细胞疗法和药物递送技术的进步推动了对高纯度血清替代品的需求不断增长，全球重组白蛋白市场持续稳步扩张。根据2024年的报告，预计该市场在2024年将达到1.428亿美元，2025年将达到1.507亿美元。预计到2032年将进一步成长至2.285亿美元，在此期间的复合年增长率（CAGR）为6.05%。亚太地区持续保持领先地位，在2024年将占全球市场的48.38%，这主要得益于不断扩大的治疗性生产能力和强劲的研发活动。

重组白蛋白因其无病毒、可扩展且符合GMP规范的生产方式，正迅速成为人类血白蛋白的替代品。其广泛的应用，包括细胞培养基、诊断、生物製剂和药物传递系统，使其成为现代生物医学製造的关键组成部分。随着细胞和基因疗法在全球的扩展，由于其稳定性、保护性和生物相容性，对重组白蛋白的需求持续成长。

市场动态

市场推动因素

市场成长的关键推动因素是重组白蛋白在细胞和基因疗法中日益广泛的应用。这些疗法需要高度稳定的添加剂，以在生产和储存过程中保护脆弱的细胞和治疗分子。重组白蛋白可以提高细胞活力、减少聚集并支持病毒载体的生产。这种日益增长的整合正在创造强劲的长期需求。例如，2021年2月，Albumedix与细胞和基因治疗加速器（Cell and Gene Therapy Catapult）合作，开始研究用于病毒载体生产的白蛋白解决方案，凸显了该公司日益增长的战略重要性。

市场限制因子

儘管成长潜力巨大，但由于重组生产的复杂性，市场面临供应限制。严格的GMP要求、昂贵的纯化技术以及与传统生物製剂相比较低的产量，都增加了生产的挑战。这些阻碍因素可能导致供应短缺和成本上升。 2022年，三菱化学集团公司因无法维持稳定的供应而停止了重组白蛋白的生产，这反映了製造商面临的挑战。

市场机会

奈米颗粒白蛋白结合（nab）药物递送系统研发的进展带来了巨大的机会。 nab技术可提高溶解度并降低毒性，使其可用于配製化疗药物和生物製剂。 2024年10月，山德士在美国推出了白蛋白结合型紫杉醇的仿製药，这标誌着基于白蛋白的给药系统正被越来越广泛地采用。肿瘤学和再生医学领域的持续进步预计将在2032年之前改善市场前景。

市场趋势

主要公司扩大产能已成为新兴的关键趋势。在先进疗法生产商需求不断增长的推动下，各公司正在投资建造更大的生物加工设施和进行上游创新。 2025年3月，烟台普济药业科技宣布扩大其重组白蛋白生产基础设施，这标誌着全球正在扩大高纯度白蛋白的供应规模。

区隔市场概览

依剂型划分

2024年，溶液剂型凭藉其降低污染风险、高均匀性和即用型等优势，占了市场主导地位。新产品的推出，包括 InVitria 于 2025 年 2 月推出的 Optibumin 25（一种用于细胞和基因治疗生产的 25% 重组白蛋白溶液），进一步巩固了该区隔市场的地位。

依应用领域划分

2024 年，治疗药物领域占了最大的市场占有率。这主要归功于重组白蛋白作为生物製剂生产中的赋形剂和稳定剂的广泛应用。持续的合作，例如 Albumedix 与 Heartseed 在 2023 年的合作，将推动重组白蛋白治疗用途的拓展。

依最终使用者划分

2024 年，製药和生技公司在最终用户领域占领先地位，这得益于其强大的研发投入、生产扩张和策略商业化协议。2024年6月，Dyadic International与Proliant Health & Biologicals合作开发重组白蛋白产品，彰显了该公司致力于扩大该领域供应的决心。

区域洞察

亚太地区仍是领先市场，2024年市场规模达6,910万美元，主要得益于生物製药活动的扩张、慢性病盛行率的上升以及区域内强有力的合作。北美市场预计到2025年将稳定成长至4,450万美元，这得益于先进的研发基础设施和强大的生物製剂生产基地。欧洲市场预计到2025年将成长至2,400万美元，主要得益于治疗药物的广泛应用。拉丁美洲以及中东和非洲地区预计将实现温和增长，这主要得益于再生医学的日益普及和医疗保健能力的提升。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 市场技术进步
  • 主要国家的监管状况（2024 年）
  • 主要公司产品线分析
  • 主要产业发展动态－併购、合作等

第五章：全球重组白蛋白市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依剂型划分
    • 粉剂
    • 溶液
  • 市场分析、洞察与预测 - 依应用划分
    • 治疗
    • 诊断
    • 研究
  • 市场分析、洞察与预测 - 依最终用户划分
    • 医院和诊所
    • 製药和生物技术
    • 研究机构
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美重组白蛋白市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲重组白蛋白市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区重组白蛋白市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲重组白蛋白市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲重组白蛋白市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

章节11 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
  • InVitria
  • FUJIFILM Wako Pure Chemical Corporation
  • Orion Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
Product Code: FBI113883

Growth Factors of recombinant albumin Market

The global recombinant albumin market continues to expand steadily as advancements in biopharmaceuticals, cell therapy, and drug delivery technologies increase the demand for high-purity serum alternatives. According to the 2024 report, the market was valued at USD 142.8 million in 2024, is expected to reach USD 150.7 million in 2025, and is forecasted to grow to USD 228.5 million by 2032, exhibiting a CAGR of 6.05% during the assessment period. Asia Pacific remained the leading region, accounting for 48.38% of the global market in 2024, supported by expanding therapeutic manufacturing capabilities and strong R&D activity.

Recombinant albumin is rapidly becoming a preferred substitute for human-derived albumin due to its virus-free, scalable, and GMP-compliant production. Its extensive applications in cell culture media, diagnostics, biologics formulation, and drug delivery systems make it a crucial component in modern biomedical manufacturing. As cell and gene therapies expand globally, demand for recombinant albumin continues to increase, driven by its stabilizing, protective, and biocompatible attributes.

Market Dynamics

Market Drivers

A major driver for market growth is the expanding adoption of recombinant albumin in cell and gene therapy. These therapies require highly stable excipients capable of protecting fragile cells and therapeutic molecules during manufacturing and storage. Recombinant albumin enhances viability, reduces aggregation, and supports viral vector manufacturing. This growing integration creates strong long-term demand. In February 2021, for example, Albumedix partnered with the Cell and Gene Therapy Catapult to investigate its albumin solutions for viral vector production, highlighting its increasing strategic importance.

Market Restraints

Despite strong growth potential, the market faces supply limitations due to the complexity of recombinant production. Strict GMP conditions, expensive purification technologies, and lower yields compared to traditional biologics increase production challenges. These constraints can lead to supply shortages and higher costs. In 2022, Mitsubishi Chemical Group Corporation discontinued its recombinant albumin production due to an inability to maintain stable supply, reflecting the difficulties faced by manufacturers.

Market Opportunities

Growing research and development in nanoparticle albumin-bound (nab) drug delivery systems presents significant opportunities. Nab technology enhances solubility and reduces toxicity, making it useful in chemotherapy and biologics formulation. In October 2024, Sandoz launched a generic paclitaxel albumin-bound formulation in the U.S., demonstrating increased adoption of albumin-based delivery systems. Continued advancements in oncology and regenerative medicine are expected to enhance market prospects through 2032.

Market Trends

A key emerging trend is the expansion of manufacturing capacity by leading players. With rising demand from advanced therapy manufacturers, companies are investing in larger bioprocessing facilities and upstream innovation. In March 2025, Yantai Projiji Pharmaceutical Technology announced the expansion of its recombinant albumin production infrastructure, indicating a global shift toward scaling high-purity albumin supply.

Segmentation Overview

By Dosage Form

The solution form dominated the market in 2024 due to reduced contamination risk, high consistency, and ready-to-use formulations. New product launches continue to strengthen this segment, including the February 2025 launch of Optibumin 25 by InVitria, a 25% recombinant albumin solution designed for cell and gene therapy manufacturing.

By Application

The therapeutics segment held the largest share in 2024, driven by recombinant albumin's wide use as an excipient and stabilizer in biologics production. Ongoing collaborations such as Albumedix's partnership with Heartseed in 2023 reinforce the expanding therapeutic applications of recombinant albumin.

By End User

Pharmaceutical and biotechnology companies dominated the end-user segment in 2024, supported by strong R&D investments, manufacturing expansion, and strategic commercialization agreements. In June 2024, Dyadic International partnered with Proliant Health & Biologicals to develop recombinant albumin products, emphasizing the sector's commitment to scaling supply.

Regional Insights

Asia Pacific remained the leading market, valued at USD 69.1 million in 2024, supported by growing biopharmaceutical activity, rising prevalence of chronic diseases, and strong regional collaborations. North America is forecasted to grow steadily, reaching USD 44.5 million by 2025, driven by advanced R&D infrastructure and a strong biologics manufacturing base. Europe is expected to expand to USD 24.0 million in 2025, supported by increasing adoption in therapeutic applications. Latin America and the Middle East & Africa are projected to grow moderately, driven by rising adoption of regenerative medicine and expanding healthcare capabilities.

Conclusion

With the market rising from USD 142.8 million in 2024 to an estimated USD 228.5 million by 2032, recombinant albumin continues to solidify its position as an essential component in biologics, advanced therapies, and drug delivery innovations. Strategic partnerships, increased manufacturing capacity, and expanding therapeutic pipelines will remain key growth drivers over the forecast period.

Segmentation By Dosage Form

  • Powder
  • Solution

By Application

  • Therapeutics
  • Diagnostics
  • Research

By End User

  • Hospital & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Geography

  • North America (By Dosage Form, Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Dosage Form, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Dosage Form, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Dosage Form, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Dosage Form, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in the Market
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.1.1. Powder
    • 5.1.2. Solutions
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutics
    • 5.2.2. Diagnostics
    • 5.2.3. Research
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.1.1. Powder
    • 6.1.2. Solution
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutics
    • 6.2.2. Diagnostics
    • 6.2.3. Research
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospital & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.1.1. Powder
    • 7.1.2. Solution
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutics
    • 7.2.2. Diagnostics
    • 7.2.3. Research
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospital & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.1.1. Powder
    • 8.1.2. Solution
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutics
    • 8.2.2. Diagnostics
    • 8.2.3. Research
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospital & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.1.1. Powder
    • 9.1.2. Solution
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutics
    • 9.2.2. Diagnostics
    • 9.2.3. Research
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospital & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Recombinant Albumin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.1.1. Powder
    • 10.1.2. Solution
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Therapeutics
    • 10.2.2. Diagnostics
    • 10.2.3. Research
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospital & Clinics
    • 10.3.2. Pharmaceutical & Biotechnology Industry
    • 10.3.3. Research Institutes
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability)
    • 11.2.1. InVitria
    • 11.2.2. FUJIFILM Wako Pure Chemical Corporation
    • 11.2.3. Orion Corporation
    • 11.2.4. Sartorius AG
    • 11.2.5. Thermo Fisher Scientific Inc.
    • 11.2.6. Merck KGaA

List of Tables

  • Table 1: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 2: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 3: Global Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 4: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 5: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 6: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 7: North America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 8: North America Recombinant Albumin Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 9: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 10: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 11: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Europe Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 14: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 15: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 16: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 18: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 19: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 20: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2019-2032
  • Table 22: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 23: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 24: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Recombinant Albumin Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Recombinant Albumin Market Value Share (%), by Dosage Form, 2024 & 2032
  • Figure 3: Global Recombinant Albumin Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Recombinant Albumin Market Value Share (%), by End User, 2024 & 2032
  • Figure 5: Global Recombinant Albumin Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Recombinant Albumin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 7: North America Recombinant Albumin Market Value Share (%), by Dosage Form, 2024
  • Figure 8: North America Recombinant Albumin Market Value (USD million), by Application, 2024 & 2032
  • Figure 9: North America Recombinant Albumin Market Value Share (%), by Application, 2024
  • Figure 10: North America Recombinant Albumin Market Value (USD million), by End User, 2024 & 2032
  • Figure 11: North America Recombinant Albumin Market Value Share (%), by End User, 2024
  • Figure 12: North America Recombinant Albumin Market Value (USD million), By Country, 2024 & 2032
  • Figure 13: North America Recombinant Albumin Market Value Share (%), By Country, 2024
  • Figure 14: Europe Recombinant Albumin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 15: Europe Recombinant Albumin Market Value Share (%), by Dosage Form, 2024
  • Figure 16: Europe Recombinant Albumin Market Value (USD million), by Application, 2024 & 2032
  • Figure 17: Europe Recombinant Albumin Market Value Share (%), by Application, 2024
  • Figure 18: Europe Recombinant Albumin Market Value (USD million), by End User, 2024 & 2032
  • Figure 19: Europe Recombinant Albumin Market Value Share (%), by End User, 2024
  • Figure 20: Europe Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Recombinant Albumin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 23: Asia Pacific Recombinant Albumin Market Value Share (%), by Dosage Form, 2024
  • Figure 24: Asia Pacific Recombinant Albumin Market Value (USD million), by Application, 2024 & 2032
  • Figure 25: Asia Pacific Recombinant Albumin Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific Recombinant Albumin Market Value (USD million), by End User, 2024 & 2032
  • Figure 27: Asia Pacific Recombinant Albumin Market Value Share (%), by End User, 2024
  • Figure 28: Asia Pacific Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Recombinant Albumin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 31: Latin America Recombinant Albumin Market Value Share (%), by Dosage Form, 2024
  • Figure 32: Latin America Recombinant Albumin Market Value (USD million), by Application, 2024 & 2032
  • Figure 33: Latin America Recombinant Albumin Market Value Share (%), by Application, 2024
  • Figure 34: Latin America Recombinant Albumin Market Value (USD million), by End User, 2024 & 2032
  • Figure 35: Latin America Recombinant Albumin Market Value Share (%), by End User, 2024
  • Figure 36: Latin America Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Recombinant Albumin Market Value (USD million), by Dosage Form, 2024 & 2032
  • Figure 39: Middle East & Africa Recombinant Albumin Market Value Share (%), by Dosage Form, 2024
  • Figure 40: Middle East & Africa Recombinant Albumin Market Value (USD million), by Application, 2024 & 2032
  • Figure 41: Middle East & Africa Recombinant Albumin Market Value Share (%), by Application, 2024
  • Figure 42: Middle East & Africa Recombinant Albumin Market Value (USD million), by End User, 2024 & 2032
  • Figure 43: Middle East & Africa Recombinant Albumin Market Value Share (%), by End User, 2024
  • Figure 44: Middle East & Africa Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Recombinant Albumin Market Share (%), By Company, 2024